IgPro20 for Acquired Immunodeficiency

This trial tests IgPro20, an immunoglobulin therapy, to determine if it can safely reduce serious bacterial infections in individuals with certain blood cancers who have undergone therapies like CAR T-cell or T-cell engager treatments. The goal is to keep the annual rate of these infections below one per year. The trial includes two groups: one for participants with lower levels of a specific protein in their blood at the start and another for those with higher levels. It seeks participants treated for blood cancers such as multiple myeloma or non-Hodgkin lymphoma who have shown a positive response to treatments like CAR T-cell therapy. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are on any prohibited therapies, including anti-infective treatments.

Research has shown that IgPro20 is as safe as other similar treatments, with side effects aligning with those typically expected for these products. In previous studies, patients with primary immunodeficiency, a condition where the immune system doesn’t function properly, have tolerated IgPro20 well.

Most treatments for acquired immunodeficiency rely on intravenous immunoglobulin (IVIG) therapies, which can be time-consuming and require hospital visits. Unlike these standard treatments, IgPro20 is unique because it is administered subcutaneously, allowing for more convenient at-home administration. This delivery method not only reduces the need for frequent hospital visits but also provides a steady release of medication, potentially improving overall efficacy and patient quality of life. Researchers are excited about IgPro20 because it offers a more flexible and patient-friendly approach to managing acquired immunodeficiency.

Research has shown that IgPro20 helps protect individuals with immune system issues from infections. It maintains sufficient levels of immunoglobulin G (IgG), a protein crucial for fighting infections. IgPro20 proves especially beneficial for those with primary immunodeficiency (PID) and secondary immunodeficiency (SID), as it helps prevent serious infections. Studies have found it safe and effective, with no unexpected side effects. The treatment strengthens the immune system, reducing the risk of bacterial infections. Participants in this trial will receive IgPro20 subcutaneously, either with an initial loading dose followed by weekly maintenance or with weekly maintenance doses only, over a total treatment duration of 52 weeks.⁶⁷⁸⁹¹⁰